FIELD: biochemistry.
SUBSTANCE: what is declared is the use of a protein having at least 69% sequence identity with a protein according to SEQ ID No: 1, in a preventive method for protecting a pig from Haemophilus parasuis infection by administering a vaccine to a pig, wherein the vaccine contains a protein as an antigen.
EFFECT: novel Haemophilus parasuis vaccine is disclosed.
9 cl, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW HAEMOPHILUS PARASUIS VACCINE | 2020 |
|
RU2822516C1 |
| VACCINE COMPOSITION AGAINST INFECTION CAUSED BY STREPTOCOCCUS SUIS | 2015 |
|
RU2735101C2 |
| VACCINE TO SWINE INFLUENZA A VIRUS | 2018 |
|
RU2787596C2 |
| IMMUNOGENIC FUSED PROTEIN | 2016 |
|
RU2757426C2 |
| VACCINE COMPOSITION AGAINST TYPE A FOOT-AND-MOUTH DISEASE VIRUS | 2018 |
|
RU2778095C2 |
| ANTIGENS AND ANTIGEN COMPOSITIONS | 2013 |
|
RU2727476C2 |
| FMDV-E2 FUSION PROTEINS AND USE THEREOF | 2016 |
|
RU2714428C2 |
| COMPOSITION FOR PREVENTING AND CURING MYCOPLASMA SPP INFECTION | 2013 |
|
RU2646137C2 |
| SWINE INFLUENZA VIRUS VACCINE CONTAINING NUCLEIC ACID CONSTRUCT HAVING SPECIFIC GENE ORDER | 2021 |
|
RU2833693C1 |
| METHOD OF INCREASING IMMUNOGENICITY OF PROTEIN/PEPTIDE ANTIGEN | 2021 |
|
RU2830627C1 |
